Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.
R Brett McQueenSeth J BaumMichael J LouieWilliam J SasielaAikaterini BilitouHemal ShahBeth NashKristin K GillardKausik K RayPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)
Further LDL-C reductions through the addition of BA+EZE FDC to maximally tolerated statins are predicted to reduce major adverse cardiovascular events compared with the addition of EZE. Benefits are potentially greater among those with higher starting LDL-C.